- Products Licensed in the US to Treat Hemophilia A
- Products Licensed in the US to Treat Hemophilia B
- Products Licensed in the US to Treat Von Willebrand Disease
- Bypassing Agents (BPA) Licensed in the US to Treat Patients with Inherited Hemophilia A or B and Inhibitors
- Non-Factor Replacement Therapies for Hemophilia A with Inhibitors
- Products Licensed in the US to Treat Non-congenital Hemophilia Patients with Acquired Hemophilia A
- Products Licensed in the US to Treat Rare Bleeding Disorders
- Factor Products Licensed in the US for Use in Individuals with Thrombosis Risk
- Blood Bank Components Licensed in the US to Treat Rare Bleeding Disorders
- Antifibrinolytic Agents
Products Licensed in the US to Treat Hemophilia A
Recombinant Factor VIII Products
- Advate
- Adynovate
- Afstyla
- Altuviiio
- Eloctate
- Esperoct
- Jivi
- Kogenate FS
- Kovaltry
- NovoEight
- NUWIQ
- Recombinate
- Xyntha
Recombinant Humanized Bispecific FIXa and FX directed monoclonal antibody for use in patients with inherited hemophilia A
Human Plasma-Derived Immunoaffinity-purified Factor VIII Concentrates
Human Plasma-derived Concentrates that Contain Factor VIII and Von Willebrand Factor
Desmopressin Formulations to Treat Mild Hemophilia A
- DDAVP Injection | Aventis Pharma
- Stimate Nasal Spray for Bleeding - Currently Unavailable
Gene Therapy
Products Licensed in the US to Treat Hemophilia B
Recombinant Factor IX Concentrates
Human Plasma-derived Coagulation Factor IX Concentrates
- AlphaNine SD (PDF to come)
- Mononine (PDF to come)
Gene Therapy
Products Licensed in the US to Treat Von Willebrand Disease
Desmopressin Formulations to Treat Type 1 and Type 2 VWD
- DDAVP Injection | Aventis Pharma
- Stimate Nasal Spray for Bleeding | CSL Behring - Currently Unavailable
Recombinant Von Willebrand Factor
Human Plasma-derived Concentrates that Contain Factor VIII and Von Willebrand Factor
Bypassing Agents (BPA) Licensed in the US to Treat Patients with Inherited Hemophilia A or B and Inhibitors
Human Plasma-derived Activated Prothrombin Complex Concentrate for Use in Patient with Inherited Hemophilia A or B and Inhibitors to Factor VIII or IX
Recombinant Factor VIIa Concentrate for Use in Patients with Inherited Hemophilia A or B and Inhibitors to Factor VIII or IX
Non-Factor Replacement Therapies Licensed in the US to Treat Patients with Inherited Hemophilia A and Inhibitors
Recombinant Humanized Bispecific FIXa and FX directed monoclonal antibody for Use in Patients with Inherited Hemophilia A and Inhibitors to Factor VIII
Products Licensed in the US to Treat Non-congenital Hemophilia Patients with Acquired Hemophilia A
Recombinant Factor Concentrates for use in patients with Acquired Inhibitors to Factor VIII
- NovoSeven RT (rhFVIIa)
- Obizur (porcine rpFVIII)
Products Licensed in the US to Treat Rare Bleeding Disorders
Human Plasma-derived Concentrate to Treat Afibrinogenemia and Hypofibrinogenemia (Factor 1 deficiency)
Recombinant Factor VIIa Concentrate for Treatment of Factor VII Deficiency
Human Plasma-derived Concentrate to Treat Factor X Deficiency
Human Plasma-Derived Concentrate to Treat Factor XIII Deficiency
Recombinant Factor XIII-A Subunit Deficiency
Human Plasma-derived Prothrombin Complex Concentrates for Use in Patients with Factor II or Factor X Deficiency
- Bebulin | Shire (Takeda)
- Profilnine (PDF to come)
Factor Products Licensed in the US for Use in Individuals with Thrombosis Risk
Products to Treat Antithrombin Deficiency
- ATryn
- Thrombate | Grifols
Human Plasma-derived Protein C Concentrate to Treat Protein C Deficiency
Product to Treat Plasminogen Deficiency
Blood Bank Components Licensed in the US to Treat Rare Bleeding Disorders
Fresh Frozen Plasma Products to Treat Patients with Factor V or Factor XI Deficiency
- Donor Retested Fresh Frozen Plasma
- Octaplas, frozen pooled plasma, blood group specific
Cryoprecipitate to Treat Patients with Dysfibrinogenemia
- Cryoprecipitate | Some Community Blood Centers
- Cryoprecipitate, pooled | Some Community Blood Centers